Clinical application of invalid foods using mealworms and evaluation of nutrition status and immune function: a study protocol for a randomized, double blind, placebo-controlled trial by 源��엫寃� et al.
STUDY PROTOCOL Open Access
Clinical application of invalid foods using
mealworms and evaluation of nutrition
status and immune function: a study
protocol for a randomized, double blind,
placebo-controlled trial
Hyung Sun Kim1, Yun Sun Lee1, Soo Yun Jang2, So Young Jun1, Jin Hong Lim1, Im Kyung Kim3,
Hyung Mi Kim2 and Joon Seong Park1*
Abstract
Background: Protein intake is important for the recovery of the immune system, physical strength, and wound
healing after surgery. Sarcopenia is associated with a poor prognosis when compared to patients without
sarcopenia in cancer patients. Recently, edible insects, such as mealworms, have been recognized as having a high
protein content. In this study, we will evaluate the effect of nutritional status and immune function change based
on a patient’s ingestion of mealworms after hepatobiliary pancreatic surgery.
Methods/design: This is a prospective, two-armed, phase III study investigating the effect of mealworm improving
nutrition and immune status in patients after hepatobiliary pancreatic surgery. In the trial group, the patients will be
provided with mealworms for 2 months after surgery. In the control group, patients will be provided with grain
powder for 2 months after surgery. The target for accrual is 168 patients. We divided in to three groups according
to the type of surgery.
Discussion: The primary endpoint is to evaluate body cell mass index 2months postoperatively. Secondary endpoints
include other body composition changes as well as nutrition index and immune function change. We expect that
ingestion of mealworms can effectively improve the nutritional status and enhance the immune function. Mealworm
can be used effectively for nutritional management of patients after surgery.
Trial registration: Clinicaltrials.gov NCT03201926 Registered June 28, 2017, retrospectively registered.
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Background
Approximately 20–50% of hospitalized patients are re-
ported to be malnourished [1]. The nutritional status of
a patient generally declines during hospitalization [2, 3].
Poor food intake during hospitalization is caused by
deterioration of nutritional status, and malnutrition is
often associated with complications including infection,
increased number of hospital days, and increased mor-
tality [1, 4, 5]. The American Society of Parenteral and
Enteral Nutrition guidelines suggests that patients at risk
of malnutrition should be provided with over 80% of
their calorie and protein requirements within 2 to 3 days
[6]. Patients with sarcopenia imbalance generally have a
lower 5-year survival rate in cancer patients [7]. The
quality of protein intake is important for the recovery of
the immune system, physical strength, and wound
healing after surgery; this is problematic since the
patient’s protein intake is generally quite poor [8].
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In particular, patients who undergo a pancreatectomy or
hepatectomy usually have a severe imbalance in their nu-
tritional status due to the disruption of digestive function
and nutritional absorption postoperatively. Therefore, it is
necessary to use high-quality protein-derived foods that
can effectively increase protein intake. The United Nations
Food and Agriculture Organization (FAO) is actively
encouraging food production of edible insects as a new
food source for the future. Currently, various insects are
used in food in many regions, including Africa, Asia,
South America, and Australia. The edible insects are high
in protein content (50–60%) and contain a large amount
of fat, fiber, vitamins, and minerals. Tenebrio molitor
(mealworm), which is an edible insect, contains a large
amount of protein and unsaturated fatty acid. The nutri-
tional components of these mealworm are thought to be
of value as nutrient sources of high quality in a small
amount of patients who need high nutrition.
The purpose of this study is to evaluate the development
of long-term personalized products using mealworm and
the enhancement of stability, nutritional status and
immune status according to ingestion.
Methods/design
Study design and period
The trial is a single center, two-armed phase III study.
The trial has been registered at www.clinicaltrials.gov
(NCT03201926). Patients will be recruited by the Pancrea-
tobiliary Cancer Clinic, Gangnam Severance Hospital,
Yonsei University College of Medicine. The expected total
duration of patient accrual is 2 years and 6months and
the follow-up period is 6months.
Study objectives and endpoints
The primary endpoint is to evaluate body cell mass
index at 2 months postoperatively. Secondary endpoints
include other body composition changes as well as
nutrition index and immune function.
Patient selection and enrollment criteria
Inclusion criteria
 Patients scheduled for surgery with pancreatobiliary
disease and liver cancer (HCC, CCC, and metastatic
liver cancer)
 Karnofsky performance status ≥70
 Patients who provide informed consent
Exclusion criteria
 Patients who underwent palliative surgery
 Patients with uncontrolled preoperative conditions
 Previous history of surgery affecting nutritional
status (ex, gastrectomy, colectomy, etc)
 Pregnant and lactating women
 Patients with an allergy to mealworms
Sample size calculation
The output of the sample size will be based on an inde-
pendent two-sample t test. It is expected that there will be
a difference in body cell mass between the standard meal
group (control) and the group ingesting the mealworms.
Assuming an alpha value of 0.05 and 1-β (power) of 0.8,
75 samples will need to be obtained for each group;
considering the dropout rate of 10%, 84 samples will need
to be obtained for each group. The total of the two groups
is 168. The primary endpoint will be the number of
subjects and body cell mass. A comparison will then be
made between the two groups at 2months. A subgroup
analysis of pancreatobiliary and liver disease will also be
performed as a secondary endpoint. Patients with
pancreatobiliary and liver disease in our clinic have a 2:1
ratio. Therefore, the 168 patients were divided into two
groups: one with 112 patients and the other with 56
patients. Patients with pancreaticobiliary disease (Group A
& B) and liver (Group C) disease were assigned through
stratified randomization. Pancreatobiliary disease group is
divided into enteral feeding group(Group A) and non
enteral feeding group.(Group B).
Pretreatment evaluation
All patients who are potential candidates for hepatopan-
creatobiliary surgery will undergo a standard evaluation
that will include contrast-enhanced computed tomography
(CT), endoluminal ultrasound (EUS), magnetic resonance
imaging (MRI), and positron emission tomography
(PET-CT), which will be discussed at the preoperative
conference.
Patients recommended for major hepatopancreatobiliary
surgery (such as a liver resection, pancreaticoduodenect-
omy, or total/distal pancreatectomy) will be contacted and
provided with a participant information sheet. Patients
will be divided into three groups according to the type of
surgery.
Treatment
Trial intervention
Patients receiving dietary supplementation with meal-
worms after their pancreatectomy, bile duct resection
and hepatectomy will be given the mealworms during
their hospitalization period and for another 2 months
after discharge. The patients in group A will undergo
enteral feeding after surgery (for those who undergo a
pancreaticoduodenectomy, nutrients will be adminis-
tered by an enteral feeding tube for early feeding while
securing the pancreatojejunostomy). A feeding nasojeju-
nal tube will be placed for patients in the enteral feeding
group. Enteral feeding (Newcare 300 RTH, Daesang,
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Korea) will start within 24 h postoperatively at a rate of
20 mL/h. The velocity will be progressively increased by
20mL/d until reaching the full nutritional goal (25 kcal/
kg). Enteral feeding will be delivered by an infusion
pump for 18 h/day with 6 h of rest.
On postoperative day 7, abdominal and pelvic CT
scans will be obtained, and if there are no complications,
we will then start patients on a clear liquid diet for 1
day. In addition, the patients will be permitted to have a
full liquid diet for 2 days and then a soft diet for 3 days
following the liquid diet.
The patients of group B will undergo oral feeding 2
days after the surgery. (distal pancreatectomy, total
pancreatectomy and bile duct resection) We will start
patient’s clear liquid diet for 1 day. The patients will be
permitted to have a full liquid diet for 2 days and soft
diet for 3 days following the liquid diet.
The patients of group C will undergo oral feeding 2
days after surgery (which includes liver resections). We
will then start the patients on a clear liquid diet for 1
day. In addition, the patients will be permitted to have a
full liquid diet for 2 days and soft diet for 3 days follow-
ing the liquid diet. The mealworm powder include 3 g of
carbohydrate, 14.4 g of protein and 11 g of fat, 163 kcal
per 30 g. (Table 1) As a result of a nutritional analysis of
mealworm powder, 10.28 g of carbohydrate, 48.26 g of
protein and 35.81 g of fat were found per 100 g. In par-
ticular, the protein includes essential amino acids as well
as many unsaturated fatty acids ranging from 76 to 80%
of the total fatty acids. In addition, iron and calcium and
other minerals were found (Table 2).
Control intervention
Patients receiving dietary supplementation with grain-
powder after pancreatectomy and hepatectomy will be
given grainpowder for their hospitalization period and 2
months after discharge. The grainpowder include 23 g of
carbohydrate, 2.9 g of protein and 0.5 g of fat, 106 kcal
per 30 g. Group A will receive the grainpowder on post-
operative day 7. And group B and C will receive grain-
powder in the same dose as trial group’s mealworms at
the start of diet at postoperative 2 days (Table 3).
Outcome measures
The primary outcome is the body cell mass index as
measured by body composition (Inbody S-10 (Biospace,
Seoul, Korea)). The secondary outcome measures are as
follows: nutritional index (weight, soft lean mass, fat free
mass, fat mass, PG-SGA [Scored Patient-Generated
Subjective Global Assessment]) and immune function
test (that assesses T cells, B cells, cytokines). We will
confirm changes in immune cells through FACS (fluor-
escence-activated cell sorting). Based on the immune
assay using blood samples from patients, we will identify
changes in several cytokines.
Timeline and recruitment
Recruitment of study participants
Once the patients’ surgery is confirmed, the research staff
will give the study staff a list of the patients. After deter-
mining the suitability of the patient, the study staff will
assign the patient to the test or control group in a ran-
domized sequence in the order in which they are enrolled.
In addition, they will be assigned in a double-blinded
manner.
Randomization
The researchers will select patients after obtaining con-
sent. Randomization will take place via an allocation
randomization system 2 days before the surgery, which
will be directed by our department. Patients will be
randomized to one of the treatment groups in a 1:1 ratio.
After consent for study enrollment is obtained, the
randomization process will be applied to identify the next
allotment. The surgeons will be blind to the allotment
throughout the enrollment process.
Blinding
Patients and all team members will be blinded to the
intervention. Adverse event (AE) and serious adverse
event (SAE) need to be reported as soon as they are
noted. This will not have any impact on the endpoint as-
sessment of the patient.
Table 1 Components of the Trial group’s diet
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Data management
The amount of food consumed by the patient daily will
be assessed as a diary entry. The researcher collects the
bags left over from the patients at the outpatient clinic.
Individual participant medical information obtained as a
result of this study is considered confidential and
disclosure to third parties is prohibited. Blood samples
transferred to the laboratory of Gangnam Severance
Hospital will be identifiable by unique trial numbers
only. Results related to nutrient indicators (Inbody,
PG-SGA) will be managed by a Gangnam Severance
Nutrition Team. The blood sample associated with
the immune function test will be transferred to the
lab of the study staff in Gangnam Severance Hospital,
which will then undergo FACS (Fluorescence-
activated cell sorting).
Withdrawal and reporting of adverse effects
If patients wish to voluntarily withdraw from the study,
the patient will be asked if they would be given medical
care until any AE symptoms resolve or the patient’s condi-
tion becomes stable.
Patients can quit the trial at any point without the
need to give reasons for their decisions. If voluntary
withdrawal occurs prior to diet intervention, the patient
will not be randomized, and no more trial data will be
collected for that patient. Patients can also withdraw
from the trial following diet intervention.
Statistical methodology
All data will be entered into a single Microsoft Excel
spreadsheet with participants identified only by their
Table 2 Menu plan and protocol of the hospital meals for the mealworm and control groups
Mealworm group Control group
Step 1 Menu
Nutrient
Energy
Protein
Carbohydrate
Fat
Carbohydrate-based liquid diet,
Mealworm jelly
580 kcal
13 g
114 g
8 g
Carbohydrate-based liquid diet,
Juice
450 kcal
16 g
84 g
6 g
Step 2 Menu
Nutrient
Energy
Protein
Carbohydrate
Fat
Mealworm soup, Mealworm shake
with berry,
Protein-fortified gelatin
1220 kcal
50 g
180 g
34 g
Carbohydrate-based liquid diet,
Thin low-fat soup,
Soybean milk, Protein-fortified
gelatin
1240 kcal
43 g
180 g
39 g
Step 3 Menu
Nutrient
Energy
Protein
Carbohydrate
Fat
Deluxe rice porridge with soft side
dishes,
ONS1)-based mealworm drink,
Mealworm tea-confectionery
1629 kcal
81 g
225 g
45 g
Rice porridge with soft side dishes
1600 kcal
75 g
235 g
40 g
Protocol The doctor prescribes Step 1 diet (clear liquid diet) as the first meal after surgery. Patients eat this diet for 2–3
meals. As the next meal, the doctor prescribes Step 2 diet (full liquid diet). Patients eat this diet for 2–3 meals. If
the diet transition goes smoothly, the doctor prescribes Step 3 diet (soft diet). Patients eat this diet until
discharge. The doctor prescribes hospital meal intake. Depending on the patient’s condition, the steps for
consuming the diet could be adjusted. The dietitian surveys the dietary intake every day until discharge. If there is
a meal-related side effect, it is reported to the doctor.
Table 3 Components of the Control group’s diet
Kim et al. BMC Nutrition            (2019) 5:44 Page 4 of 6
unique subject number. All entries will be double-checked
by another member of the research team. Statistical ana-
lysis will be performed using IBM SPSS version 21.0 (IBM
Corp; released 2012. IBM SPSS Statistics for Windows
Version 21.0. Armonk, NY, USA). The mean difference in
nutrient intakes, changes in body measurements, changes
in body composition, and PG-SGA scores will be calcu-
lated using the Wilcoxon signed rank test and the Mann
Whitney test.
Monitoring and follow-up period
The research team is responsible for monitoring the
study. At 1 week after discharge, the participants are
asked whether they are willing to continue ingesting the
mealworm. Every 2 weeks after the patients visit their
outpatient clinic, the monitoring researcher will check
whether they are taking the mealworm regularly. The re-
search team is also responsible for systematically review-
ing the causes of withdrawal from the study. Assessment
of these changes will be determined 2months after sur-
gery (Table 4).
Ethical and legal considerations
The study protocol was approved by the institutional re-
view board at Gangnam Severance Hospital, Yonsei Uni-
versity of Korea (3–2017-0077). The study complies with
the Declaration of Helsinki and the principles of Good
Clinical Practice.
Discussion
The aim of this study is to evaluate the effectiveness and
improvement of nutritional status and immune function
based on the intake of invalid foods in postoperative pa-
tients for major surgery (such surgery of the pancreas, bile
duct and liver) after an intervention period of 2months.
Nutritional deficiencies are frequent in patients after ab-
dominal surgery. Malnutrition is an important risk factor
for developing sarcopenia [9–12]. The decrease in the
amount of fat free mass is associated with an increased
mortality rate in patients at risk of malnutrition such as
surgery and critical illness [13]. Protein-enhanced diets are
known to increase survival in these patients, and therefore,
nutritional support using high-protein foods is important
[14]. Based on studies such as these, high protein foods
using mealworm are now being used. However, only a few
studies have evaluated the enhancement of immune
function in patients after intake of high protein foods. In
other studies, immune function evaluations were reported
[15, 16]. Early enteral nutrition after esophageal cancer
surgery can effectively improve the nutritional status and
enhance the immune function [15] . Some markers of
immune function may be useful for distinguishing patients
with good or bad prognoses after head and neck cancer
surgery by checking the cytokine levels [16] . However,
there are no studies on the effects of long term use (2
months) of high protein mealworm that can be used
effectively for nutritional management of patients after
surgery. This will be the first study to directly identify the
relationship between nutritional status and immune
function after surgery.
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